Sionna Therapeutics (SION)

Executive Summary

Sionna Therapeutics is a clinical-stage biopharmaceutical company developing novel small molecule drugs for cystic fibrosis (CF) by targeting the root cause of the disease—defective CFTR protein function. Unlike current CFTR modulators that address specific mutations, Sionna's approach stabilizes the first nucleotide-binding domain (NBD1) of CFTR, a mechanism relevant to a broad patient population. The company's pipeline includes two key programs: a Phase 2 monotherapy trial of SION-719 (NCT07108153) and a Phase 1 combination trial of SION-451, SION-2222, and SION-109 (NCT07035990). Both trials are recruiting and targeting completion in mid-2026. Sionna's differentiated science addresses a significant unmet need for CF patients who are non-responsive to or intolerant of existing therapies, representing a substantial market opportunity. As a public company (NASDAQ: SION) with a market capitalization of approximately $1.65 billion, Sionna is well-capitalized to advance its pipeline through key clinical milestones. Success in these trials could position Sionna as a leader in next-generation CF treatments and drive significant value for shareholders.

Upcoming Catalysts (preview)

• Q2 2026Phase 1 Combination Trial (NCT07035990) Data Readout70% success
• Q3 2026Phase 2 Monotherapy Trial (NCT07108153) Data Readout60% success
• Q4 2026Potential FDA Guidance on Phase 3 Program Design80% success